middle.news
Argenica Clears Final FDA Safety Hurdle for ARG-007, Eyes Phase 2b Trial Start
8:33am on Thursday 11th of June, 2026 AEST
•
Biotechnology
Read Story
Argenica Clears Final FDA Safety Hurdle for ARG-007, Eyes Phase 2b Trial Start
8:33am on Thursday 11th of June, 2026 AEST
Key Points
ARG-007 shows no cardiac hERG channel inhibition
All three FDA safety assays completed with clean profiles
Phase 2b trial protocol nearing finalisation
Comprehensive FDA clinical hold response imminent
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argenica Therapeutics (ASX:AGN)
OPEN ARTICLE